JP2014523901A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014523901A5 JP2014523901A5 JP2014519057A JP2014519057A JP2014523901A5 JP 2014523901 A5 JP2014523901 A5 JP 2014523901A5 JP 2014519057 A JP2014519057 A JP 2014519057A JP 2014519057 A JP2014519057 A JP 2014519057A JP 2014523901 A5 JP2014523901 A5 JP 2014523901A5
- Authority
- JP
- Japan
- Prior art keywords
- benzamide
- fluoro
- phenyl
- chloro
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 150000003839 salts Chemical group 0.000 claims description 6
- 150000004677 hydrates Chemical class 0.000 claims description 5
- BBLXLHYPDOMJMO-UHFFFAOYSA-N 5-(butan-2-ylsulfamoyl)-n-(3,4-difluorophenyl)-2-fluorobenzamide Chemical compound CCC(C)NS(=O)(=O)C1=CC=C(F)C(C(=O)NC=2C=C(F)C(F)=CC=2)=C1 BBLXLHYPDOMJMO-UHFFFAOYSA-N 0.000 claims description 3
- DIBFYUJKGFSYSJ-UHFFFAOYSA-N 5-(cyclohexylsulfamoyl)-n-(3,4-difluorophenyl)-2-fluorobenzamide Chemical compound C1=C(F)C(F)=CC=C1NC(=O)C1=CC(S(=O)(=O)NC2CCCCC2)=CC=C1F DIBFYUJKGFSYSJ-UHFFFAOYSA-N 0.000 claims description 3
- ZSAVPNCDVFOTNN-UHFFFAOYSA-N 5-(cyclopentylsulfamoyl)-n-(3,4-difluorophenyl)-2-fluorobenzamide Chemical compound C1=C(F)C(F)=CC=C1NC(=O)C1=CC(S(=O)(=O)NC2CCCC2)=CC=C1F ZSAVPNCDVFOTNN-UHFFFAOYSA-N 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 7
- 229910052801 chlorine Inorganic materials 0.000 claims 7
- 239000000460 chlorine Substances 0.000 claims 7
- 150000002431 hydrogen Chemical class 0.000 claims 6
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 4
- 241000700721 Hepatitis B virus Species 0.000 claims 4
- 239000000562 conjugate Substances 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 229910052731 fluorine Inorganic materials 0.000 claims 4
- 239000011737 fluorine Substances 0.000 claims 4
- 208000015181 infectious disease Diseases 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 229940002612 prodrug Drugs 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- YTTWDIOCTVIQJQ-UHFFFAOYSA-N 2-bromo-5-(cyclohexylsulfamoyl)-n-phenylbenzamide Chemical compound BrC1=CC=C(S(=O)(=O)NC2CCCCC2)C=C1C(=O)NC1=CC=CC=C1 YTTWDIOCTVIQJQ-UHFFFAOYSA-N 0.000 claims 1
- FNUCPIHCITUGQE-UHFFFAOYSA-N 2-chloro-n-(3-methylphenyl)-5-sulfamoylbenzamide Chemical compound CC1=CC=CC(NC(=O)C=2C(=CC=C(C=2)S(N)(=O)=O)Cl)=C1 FNUCPIHCITUGQE-UHFFFAOYSA-N 0.000 claims 1
- NRRAAVBIZGRKFF-UHFFFAOYSA-N 2-fluoro-5-[(4-fluorophenyl)sulfamoyl]-n-(3-methylphenyl)benzamide Chemical compound CC1=CC=CC(NC(=O)C=2C(=CC=C(C=2)S(=O)(=O)NC=2C=CC(F)=CC=2)F)=C1 NRRAAVBIZGRKFF-UHFFFAOYSA-N 0.000 claims 1
- ZKYVPYFRGZNHJT-UHFFFAOYSA-N 2-fluoro-5-[(4-methoxyphenyl)sulfamoyl]-n-(3-methylphenyl)benzamide Chemical compound C1=CC(OC)=CC=C1NS(=O)(=O)C1=CC=C(F)C(C(=O)NC=2C=C(C)C=CC=2)=C1 ZKYVPYFRGZNHJT-UHFFFAOYSA-N 0.000 claims 1
- MPCMNARIWULMFJ-UHFFFAOYSA-N 2-fluoro-n-(3-fluorophenyl)-5-(furan-2-ylmethylsulfamoyl)benzamide Chemical compound FC1=CC=CC(NC(=O)C=2C(=CC=C(C=2)S(=O)(=O)NCC=2OC=CC=2)F)=C1 MPCMNARIWULMFJ-UHFFFAOYSA-N 0.000 claims 1
- PBAWFYZFSXYUOS-UHFFFAOYSA-N 3-(azepan-1-ylsulfonyl)-n-benzyl-4-chlorobenzamide Chemical compound ClC1=CC=C(C(=O)NCC=2C=CC=CC=2)C=C1S(=O)(=O)N1CCCCCC1 PBAWFYZFSXYUOS-UHFFFAOYSA-N 0.000 claims 1
- KEZNVHQUQCVDAX-UHFFFAOYSA-N 3-(cyclohexylsulfamoyl)-4-methyl-n-phenylbenzamide Chemical compound CC1=CC=C(C(=O)NC=2C=CC=CC=2)C=C1S(=O)(=O)NC1CCCCC1 KEZNVHQUQCVDAX-UHFFFAOYSA-N 0.000 claims 1
- WFDUMBOKYBAJST-UHFFFAOYSA-N 3-(cyclopentylsulfamoyl)-4-fluoro-n-(3-methylphenyl)benzamide Chemical compound CC1=CC=CC(NC(=O)C=2C=C(C(F)=CC=2)S(=O)(=O)NC2CCCC2)=C1 WFDUMBOKYBAJST-UHFFFAOYSA-N 0.000 claims 1
- TVUAZFKFLYTZMI-UHFFFAOYSA-N 3-(cyclopentylsulfamoyl)-n-phenylbenzamide Chemical compound C=1C=CC(S(=O)(=O)NC2CCCC2)=CC=1C(=O)NC1=CC=CC=C1 TVUAZFKFLYTZMI-UHFFFAOYSA-N 0.000 claims 1
- DPONBEDTMNFWFV-UHFFFAOYSA-N 3-(diethylsulfamoyl)-n-phenylbenzamide Chemical compound CCN(CC)S(=O)(=O)C1=CC=CC(C(=O)NC=2C=CC=CC=2)=C1 DPONBEDTMNFWFV-UHFFFAOYSA-N 0.000 claims 1
- VFQPLEJOOLNBTH-UHFFFAOYSA-N 3-(furan-2-ylmethylsulfamoyl)-n-phenylbenzamide Chemical compound C=1C=CC(S(=O)(=O)NCC=2OC=CC=2)=CC=1C(=O)NC1=CC=CC=C1 VFQPLEJOOLNBTH-UHFFFAOYSA-N 0.000 claims 1
- KIQGAHCODFLQIZ-UHFFFAOYSA-N 3-[(2-methylphenyl)sulfamoyl]-n-phenylbenzamide Chemical compound CC1=CC=CC=C1NS(=O)(=O)C1=CC=CC(C(=O)NC=2C=CC=CC=2)=C1 KIQGAHCODFLQIZ-UHFFFAOYSA-N 0.000 claims 1
- YVEKYUJVYNNGIM-UHFFFAOYSA-N 3-[(3-methylphenyl)sulfamoyl]-n-phenylbenzamide Chemical compound CC1=CC=CC(NS(=O)(=O)C=2C=C(C=CC=2)C(=O)NC=2C=CC=CC=2)=C1 YVEKYUJVYNNGIM-UHFFFAOYSA-N 0.000 claims 1
- QPCNWXKARWHIMY-UHFFFAOYSA-N 3-[[3-(benzylcarbamoyl)phenyl]sulfonylamino]benzoic acid Chemical compound OC(=O)C1=CC=CC(NS(=O)(=O)C=2C=C(C=CC=2)C(=O)NCC=2C=CC=CC=2)=C1 QPCNWXKARWHIMY-UHFFFAOYSA-N 0.000 claims 1
- SDQANSXWGDCZHL-UHFFFAOYSA-N 3-[benzyl(ethyl)sulfamoyl]-n-(3,4-difluorophenyl)-4-fluorobenzamide Chemical compound C=1C(C(=O)NC=2C=C(F)C(F)=CC=2)=CC=C(F)C=1S(=O)(=O)N(CC)CC1=CC=CC=C1 SDQANSXWGDCZHL-UHFFFAOYSA-N 0.000 claims 1
- MAPCCQHYDIBUOE-UHFFFAOYSA-N 4-chloro-3-(cyclohexylsulfamoyl)-n-(4-fluorophenyl)benzamide Chemical compound C1=CC(F)=CC=C1NC(=O)C1=CC=C(Cl)C(S(=O)(=O)NC2CCCCC2)=C1 MAPCCQHYDIBUOE-UHFFFAOYSA-N 0.000 claims 1
- QDNZYNPFXOYFFH-UHFFFAOYSA-N 4-chloro-n-(3-fluorophenyl)-3-morpholin-4-ylsulfonylbenzamide Chemical compound FC1=CC=CC(NC(=O)C=2C=C(C(Cl)=CC=2)S(=O)(=O)N2CCOCC2)=C1 QDNZYNPFXOYFFH-UHFFFAOYSA-N 0.000 claims 1
- TWVONQXJEQBVIQ-UHFFFAOYSA-N 4-chloro-n-(4-fluorophenyl)-3-piperidin-1-ylsulfonylbenzamide Chemical compound C1=CC(F)=CC=C1NC(=O)C1=CC=C(Cl)C(S(=O)(=O)N2CCCCC2)=C1 TWVONQXJEQBVIQ-UHFFFAOYSA-N 0.000 claims 1
- JSZVDCAAQWXMCQ-UHFFFAOYSA-N 4-chloro-n-phenyl-3-thiomorpholin-4-ylsulfonylbenzamide Chemical compound ClC1=CC=C(C(=O)NC=2C=CC=CC=2)C=C1S(=O)(=O)N1CCSCC1 JSZVDCAAQWXMCQ-UHFFFAOYSA-N 0.000 claims 1
- WPMSBSXBLNTLGB-UHFFFAOYSA-N 4-fluoro-3-(furan-2-ylmethylsulfamoyl)-n-(3-methylphenyl)benzamide Chemical compound CC1=CC=CC(NC(=O)C=2C=C(C(F)=CC=2)S(=O)(=O)NCC=2OC=CC=2)=C1 WPMSBSXBLNTLGB-UHFFFAOYSA-N 0.000 claims 1
- ZHWVUVOALLPLDK-UHFFFAOYSA-N 4-fluoro-3-sulfamoyl-n-[3-(trifluoromethyl)phenyl]benzamide Chemical compound C1=C(F)C(S(=O)(=O)N)=CC(C(=O)NC=2C=C(C=CC=2)C(F)(F)F)=C1 ZHWVUVOALLPLDK-UHFFFAOYSA-N 0.000 claims 1
- QSNRCGNYLFXFOX-UHFFFAOYSA-N 4-methyl-n-phenyl-3-piperidin-1-ylsulfonylbenzamide Chemical compound CC1=CC=C(C(=O)NC=2C=CC=CC=2)C=C1S(=O)(=O)N1CCCCC1 QSNRCGNYLFXFOX-UHFFFAOYSA-N 0.000 claims 1
- LQSVIKKUGQAEBP-UHFFFAOYSA-N 5-(azepan-1-ylsulfonyl)-n-(3,4-difluorophenyl)-2-fluorobenzamide Chemical compound C1=C(F)C(F)=CC=C1NC(=O)C1=CC(S(=O)(=O)N2CCCCCC2)=CC=C1F LQSVIKKUGQAEBP-UHFFFAOYSA-N 0.000 claims 1
- XOYCHWHQJKTPKY-UHFFFAOYSA-N 5-(benzylsulfamoyl)-2-chloro-n-phenylbenzamide Chemical compound ClC1=CC=C(S(=O)(=O)NCC=2C=CC=CC=2)C=C1C(=O)NC1=CC=CC=C1 XOYCHWHQJKTPKY-UHFFFAOYSA-N 0.000 claims 1
- KYKKHEPFCUUKQU-UHFFFAOYSA-N 5-(benzylsulfamoyl)-n-(3-chloro-4-fluorophenyl)-2-fluorobenzamide Chemical compound C1=C(Cl)C(F)=CC=C1NC(=O)C1=CC(S(=O)(=O)NCC=2C=CC=CC=2)=CC=C1F KYKKHEPFCUUKQU-UHFFFAOYSA-N 0.000 claims 1
- OGAJDFDTOUWQTL-UHFFFAOYSA-N 5-(cycloheptylsulfamoyl)-n-(3,4-difluorophenyl)-2-fluorobenzamide Chemical compound C1=C(F)C(F)=CC=C1NC(=O)C1=CC(S(=O)(=O)NC2CCCCCC2)=CC=C1F OGAJDFDTOUWQTL-UHFFFAOYSA-N 0.000 claims 1
- VWXZMUJTTIZYMN-UHFFFAOYSA-N 5-(cyclopentylsulfamoyl)-2-fluoro-n-(4-fluorophenyl)benzamide Chemical compound C1=CC(F)=CC=C1NC(=O)C1=CC(S(=O)(=O)NC2CCCC2)=CC=C1F VWXZMUJTTIZYMN-UHFFFAOYSA-N 0.000 claims 1
- COIGKRMQVNURRO-UHFFFAOYSA-N 5-(cyclopentylsulfamoyl)-n-(3,5-dichlorophenyl)-2-fluorobenzamide Chemical compound FC1=CC=C(S(=O)(=O)NC2CCCC2)C=C1C(=O)NC1=CC(Cl)=CC(Cl)=C1 COIGKRMQVNURRO-UHFFFAOYSA-N 0.000 claims 1
- XEDMIPPPLRMEDD-UHFFFAOYSA-N 5-(cyclopentylsulfamoyl)-n-(3,5-dimethylphenyl)-2-fluorobenzamide Chemical compound CC1=CC(C)=CC(NC(=O)C=2C(=CC=C(C=2)S(=O)(=O)NC2CCCC2)F)=C1 XEDMIPPPLRMEDD-UHFFFAOYSA-N 0.000 claims 1
- ZHJPAXADDOFOOA-UHFFFAOYSA-N 5-(diethylsulfamoyl)-n-(3,4-difluorophenyl)-2-fluorobenzamide Chemical compound CCN(CC)S(=O)(=O)C1=CC=C(F)C(C(=O)NC=2C=C(F)C(F)=CC=2)=C1 ZHJPAXADDOFOOA-UHFFFAOYSA-N 0.000 claims 1
- SXWOBZCNPAWIMT-UHFFFAOYSA-N 5-[(2-chlorophenyl)methylsulfamoyl]-n-(3,4-difluorophenyl)-2-fluorobenzamide Chemical compound C1=C(F)C(F)=CC=C1NC(=O)C1=CC(S(=O)(=O)NCC=2C(=CC=CC=2)Cl)=CC=C1F SXWOBZCNPAWIMT-UHFFFAOYSA-N 0.000 claims 1
- ANYRROIODVIJMW-UHFFFAOYSA-N 5-[2-(cyclohexen-1-yl)ethylsulfamoyl]-n-(3,5-dimethylphenyl)-2-fluorobenzamide Chemical compound CC1=CC(C)=CC(NC(=O)C=2C(=CC=C(C=2)S(=O)(=O)NCCC=2CCCCC=2)F)=C1 ANYRROIODVIJMW-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- JWGKMOUUSKAEMG-UHFFFAOYSA-N methyl 5-[[[4-chloro-3-(phenylcarbamoyl)phenyl]sulfonylamino]methyl]furan-2-carboxylate Chemical compound O1C(C(=O)OC)=CC=C1CNS(=O)(=O)C1=CC=C(Cl)C(C(=O)NC=2C=CC=CC=2)=C1 JWGKMOUUSKAEMG-UHFFFAOYSA-N 0.000 claims 1
- YTEPBXQPDFTBDV-UHFFFAOYSA-N n-(3,4-difluorophenyl)-2-fluoro-5-(2-phenylethylsulfamoyl)benzamide Chemical compound C1=C(F)C(F)=CC=C1NC(=O)C1=CC(S(=O)(=O)NCCC=2C=CC=CC=2)=CC=C1F YTEPBXQPDFTBDV-UHFFFAOYSA-N 0.000 claims 1
- KVUYYMSVYWAUHA-UHFFFAOYSA-N n-(3,4-difluorophenyl)-4-fluoro-3-[(2-methylcyclohexyl)sulfamoyl]benzamide Chemical compound CC1CCCCC1NS(=O)(=O)C1=CC(C(=O)NC=2C=C(F)C(F)=CC=2)=CC=C1F KVUYYMSVYWAUHA-UHFFFAOYSA-N 0.000 claims 1
- GNYLBBUBZYNWMA-UHFFFAOYSA-N n-(3,4-difluorophenyl)-5-(dipropylsulfamoyl)-2-fluorobenzamide Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(F)C(C(=O)NC=2C=C(F)C(F)=CC=2)=C1 GNYLBBUBZYNWMA-UHFFFAOYSA-N 0.000 claims 1
- RNVYVZZFNFIOGY-UHFFFAOYSA-N n-(3,5-dichlorophenyl)-2-fluoro-5-(furan-2-ylmethylsulfamoyl)benzamide Chemical compound FC1=CC=C(S(=O)(=O)NCC=2OC=CC=2)C=C1C(=O)NC1=CC(Cl)=CC(Cl)=C1 RNVYVZZFNFIOGY-UHFFFAOYSA-N 0.000 claims 1
- SQXYIAWQRSLCGK-UHFFFAOYSA-N n-(3-chloro-4-fluorophenyl)-2-fluoro-5-(furan-2-ylmethylsulfamoyl)benzamide Chemical compound C1=C(Cl)C(F)=CC=C1NC(=O)C1=CC(S(=O)(=O)NCC=2OC=CC=2)=CC=C1F SQXYIAWQRSLCGK-UHFFFAOYSA-N 0.000 claims 1
- GGBVCFRVKITRFL-UHFFFAOYSA-N n-(3-chlorophenyl)-2-fluoro-5-(2-phenylethylsulfamoyl)benzamide Chemical compound FC1=CC=C(S(=O)(=O)NCCC=2C=CC=CC=2)C=C1C(=O)NC1=CC=CC(Cl)=C1 GGBVCFRVKITRFL-UHFFFAOYSA-N 0.000 claims 1
- NPEYKKPRQOFFDQ-UHFFFAOYSA-N n-(3-chlorophenyl)-4-fluoro-3-(pyridin-3-ylmethylsulfamoyl)benzamide Chemical compound FC1=CC=C(C(=O)NC=2C=C(Cl)C=CC=2)C=C1S(=O)(=O)NCC1=CC=CN=C1 NPEYKKPRQOFFDQ-UHFFFAOYSA-N 0.000 claims 1
- YIGUUMSVCOYTDS-UHFFFAOYSA-N n-(3-chlorophenyl)-5-[2-(cyclohexen-1-yl)ethylsulfamoyl]-2-fluorobenzamide Chemical compound FC1=CC=C(S(=O)(=O)NCCC=2CCCCC=2)C=C1C(=O)NC1=CC=CC(Cl)=C1 YIGUUMSVCOYTDS-UHFFFAOYSA-N 0.000 claims 1
- HGYFGBSBOAUQHG-UHFFFAOYSA-N n-(4-chlorophenyl)-3-(diethylsulfamoyl)benzamide Chemical compound CCN(CC)S(=O)(=O)C1=CC=CC(C(=O)NC=2C=CC(Cl)=CC=2)=C1 HGYFGBSBOAUQHG-UHFFFAOYSA-N 0.000 claims 1
- MCWYIVFETHLTHK-UHFFFAOYSA-N n-(4-chlorophenyl)-3-[(2-chlorophenyl)methylsulfamoyl]-4-fluorobenzamide Chemical compound FC1=CC=C(C(=O)NC=2C=CC(Cl)=CC=2)C=C1S(=O)(=O)NCC1=CC=CC=C1Cl MCWYIVFETHLTHK-UHFFFAOYSA-N 0.000 claims 1
- YAFODRLJFSCWHU-UHFFFAOYSA-N n-(4-chlorophenyl)-3-[(2-methylphenyl)sulfamoyl]benzamide Chemical compound CC1=CC=CC=C1NS(=O)(=O)C1=CC=CC(C(=O)NC=2C=CC(Cl)=CC=2)=C1 YAFODRLJFSCWHU-UHFFFAOYSA-N 0.000 claims 1
- QMHDIYFUNSUQKI-UHFFFAOYSA-N n-(4-chlorophenyl)-3-[(3-fluorophenyl)sulfamoyl]benzamide Chemical compound FC1=CC=CC(NS(=O)(=O)C=2C=C(C=CC=2)C(=O)NC=2C=CC(Cl)=CC=2)=C1 QMHDIYFUNSUQKI-UHFFFAOYSA-N 0.000 claims 1
- CKYXLFLJAUDXPD-UHFFFAOYSA-N n-(4-chlorophenyl)-5-[2-(3,4-dimethoxyphenyl)ethylsulfamoyl]-2-fluorobenzamide Chemical compound C1=C(OC)C(OC)=CC=C1CCNS(=O)(=O)C1=CC=C(F)C(C(=O)NC=2C=CC(Cl)=CC=2)=C1 CKYXLFLJAUDXPD-UHFFFAOYSA-N 0.000 claims 1
- ZMBJURWSFGFJRY-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-4-fluoro-3-sulfamoylbenzamide Chemical compound C1=C(F)C(S(=O)(=O)N)=CC(C(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)=C1 ZMBJURWSFGFJRY-UHFFFAOYSA-N 0.000 claims 1
- QPISBSFLDIZASE-UHFFFAOYSA-N n-benzyl-3-(benzylsulfamoyl)-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NCC=2C=CC=CC=2)C=C1S(=O)(=O)NCC1=CC=CC=C1 QPISBSFLDIZASE-UHFFFAOYSA-N 0.000 claims 1
- MQCJWNAWLZTGQX-UHFFFAOYSA-N n-benzyl-4-bromo-3-(diethylsulfamoyl)benzamide Chemical compound C1=C(Br)C(S(=O)(=O)N(CC)CC)=CC(C(=O)NCC=2C=CC=CC=2)=C1 MQCJWNAWLZTGQX-UHFFFAOYSA-N 0.000 claims 1
- DCADFUUGMOJXGT-UHFFFAOYSA-N n-benzyl-4-chloro-3-piperidin-1-ylsulfonylbenzamide Chemical compound ClC1=CC=C(C(=O)NCC=2C=CC=CC=2)C=C1S(=O)(=O)N1CCCCC1 DCADFUUGMOJXGT-UHFFFAOYSA-N 0.000 claims 1
- DQBFOWJYVZUYLC-UHFFFAOYSA-N n-benzyl-4-methyl-3-(4-methylpiperidin-1-yl)sulfonylbenzamide Chemical compound C1CC(C)CCN1S(=O)(=O)C1=CC(C(=O)NCC=2C=CC=CC=2)=CC=C1C DQBFOWJYVZUYLC-UHFFFAOYSA-N 0.000 claims 1
- RPVXKBFDFCOLQP-UHFFFAOYSA-N n-phenyl-3-(pyridin-3-ylmethylsulfamoyl)benzamide Chemical compound C=1C=CC(S(=O)(=O)NCC=2C=NC=CC=2)=CC=1C(=O)NC1=CC=CC=C1 RPVXKBFDFCOLQP-UHFFFAOYSA-N 0.000 claims 1
- GJXPMGCXUXSFJW-UHFFFAOYSA-N n-phenyl-3-sulfamoylbenzamide Chemical compound NS(=O)(=O)C1=CC=CC(C(=O)NC=2C=CC=CC=2)=C1 GJXPMGCXUXSFJW-UHFFFAOYSA-N 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- AXNUZKSSQHTNPZ-UHFFFAOYSA-N 3,4-difluoroaniline Chemical compound NC1=CC=C(F)C(F)=C1 AXNUZKSSQHTNPZ-UHFFFAOYSA-N 0.000 description 3
- CISMZCVQNVNWJW-UHFFFAOYSA-N 5-chlorosulfonyl-2-fluorobenzoic acid Chemical compound OC(=O)C1=CC(S(Cl)(=O)=O)=CC=C1F CISMZCVQNVNWJW-UHFFFAOYSA-N 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000003810 ethyl acetate extraction Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- LJMXGSOXXVIIBX-UHFFFAOYSA-N 5-(butan-2-ylsulfamoyl)-2-fluorobenzoic acid Chemical compound CCC(C)NS(=O)(=O)C1=CC=C(F)C(C(O)=O)=C1 LJMXGSOXXVIIBX-UHFFFAOYSA-N 0.000 description 1
- TVMQMTHQSPBXJO-UHFFFAOYSA-N 5-(cyclohexylsulfamoyl)-2-fluorobenzoic acid Chemical compound C1=C(F)C(C(=O)O)=CC(S(=O)(=O)NC2CCCCC2)=C1 TVMQMTHQSPBXJO-UHFFFAOYSA-N 0.000 description 1
- FWZLBJWLCHVGSO-UHFFFAOYSA-N 5-(cyclopentylsulfamoyl)-2-fluorobenzoic acid Chemical compound C1=C(F)C(C(=O)O)=CC(S(=O)(=O)NC2CCCC2)=C1 FWZLBJWLCHVGSO-UHFFFAOYSA-N 0.000 description 1
- JPYQFYIEOUVJDU-UHFFFAOYSA-N beclamide Chemical compound ClCCC(=O)NCC1=CC=CC=C1 JPYQFYIEOUVJDU-UHFFFAOYSA-N 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- -1 patches Substances 0.000 description 1
- BHRZNVHARXXAHW-UHFFFAOYSA-N sec-butylamine Chemical compound CCC(C)N BHRZNVHARXXAHW-UHFFFAOYSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161503830P | 2011-07-01 | 2011-07-01 | |
| US61/503,830 | 2011-07-01 | ||
| PCT/US2012/044775 WO2013006394A1 (en) | 2011-07-01 | 2012-06-29 | Sulfamoylbenzamide derivatives as antiviral agents against hbv infection |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016143481A Division JP6516705B2 (ja) | 2011-07-01 | 2016-07-21 | Ｈｂｖ感染に対する抗ウイルス剤としてのスルファモイルベンズアミド誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014523901A JP2014523901A (ja) | 2014-09-18 |
| JP2014523901A5 true JP2014523901A5 (https=) | 2015-08-20 |
| JP5977347B2 JP5977347B2 (ja) | 2016-08-24 |
Family
ID=47437368
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014519057A Expired - Fee Related JP5977347B2 (ja) | 2011-07-01 | 2012-06-29 | Ｈｂｖ感染に対する抗ウイルス剤としてのスルファモイルベンズアミド誘導体 |
| JP2016143481A Expired - Fee Related JP6516705B2 (ja) | 2011-07-01 | 2016-07-21 | Ｈｂｖ感染に対する抗ウイルス剤としてのスルファモイルベンズアミド誘導体 |
| JP2019077562A Pending JP2019151639A (ja) | 2011-07-01 | 2019-04-16 | Ｈｂｖ感染に対する抗ウイルス剤としてのスルファモイルベンズアミド誘導体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016143481A Expired - Fee Related JP6516705B2 (ja) | 2011-07-01 | 2016-07-21 | Ｈｂｖ感染に対する抗ウイルス剤としてのスルファモイルベンズアミド誘導体 |
| JP2019077562A Pending JP2019151639A (ja) | 2011-07-01 | 2019-04-16 | Ｈｂｖ感染に対する抗ウイルス剤としてのスルファモイルベンズアミド誘導体 |
Country Status (5)
| Country | Link |
|---|---|
| US (5) | US9399619B2 (https=) |
| EP (2) | EP3085368A1 (https=) |
| JP (3) | JP5977347B2 (https=) |
| CN (2) | CN103889953B (https=) |
| WO (1) | WO2013006394A1 (https=) |
Families Citing this family (127)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3085368A1 (en) | 2011-07-01 | 2016-10-26 | Baruch S. Blumberg Institute | Sulfamoylbenzamide derivatives as antiviral agents against hbv infection |
| WO2013096744A1 (en) | 2011-12-21 | 2013-06-27 | Novira Therapeutics, Inc. | Hepatitis b antiviral agents |
| EA026957B1 (ru) | 2012-08-28 | 2017-06-30 | Янссен Сайенсиз Айрлэнд Юси | Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b |
| EA038942B1 (ru) | 2012-08-28 | 2021-11-12 | Янссен Сайенсиз Айрлэнд Юси | Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b |
| CN105209031A (zh) * | 2012-12-27 | 2015-12-30 | 德雷克塞尔大学 | 针对hbv感染的新型抗病毒剂 |
| HUE034820T2 (en) | 2013-02-28 | 2018-02-28 | Janssen Sciences Ireland Uc | Sulphamoyl arylamides and their use as medicaments for the treatment of hepatitis B |
| US8993771B2 (en) | 2013-03-12 | 2015-03-31 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
| EA027068B1 (ru) * | 2013-04-03 | 2017-06-30 | Янссен Сайенсиз Айрлэнд Юси | Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b |
| TWI651300B (zh) * | 2013-05-17 | 2019-02-21 | 健生科學愛爾蘭無限公司 | 胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途 |
| EA035500B1 (ru) * | 2013-05-17 | 2020-06-25 | Янссен Сайенсиз Айрлэнд Юси | Производные сульфамоилтиофенамида и их применение в качестве медикаментов для лечения гепатита b |
| DK3024819T3 (en) * | 2013-07-25 | 2018-06-06 | Janssen Sciences Ireland Uc | GLYOXAMIDE-SUBSTITUTED PYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICINES FOR TREATING HEPATITIS B |
| KR102290189B1 (ko) * | 2013-10-23 | 2021-08-17 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 카르복스아미드 유도체 및 ｂ형 간염 치료용 의약으로서의 이의 용도 |
| AU2014348518B2 (en) | 2013-11-14 | 2019-01-03 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US9169212B2 (en) * | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US9181288B2 (en) | 2014-01-16 | 2015-11-10 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| JP6553059B2 (ja) | 2014-02-05 | 2019-07-31 | ノヴィラ・セラピューティクス・インコーポレイテッド | Ｈｂｖ感染の治療のための併用療法 |
| WO2015118057A1 (en) | 2014-02-06 | 2015-08-13 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| PT3116316T (pt) * | 2014-03-13 | 2019-09-30 | Assembly Biosciences Inc | Moduladores alostéricos da proteína do núcleo da hepatite b |
| US9400280B2 (en) | 2014-03-27 | 2016-07-26 | Novira Therapeutics, Inc. | Piperidine derivatives and methods of treating hepatitis B infections |
| CA2948580A1 (en) * | 2014-05-09 | 2015-11-12 | Adam Zlotnick | Methods and compositions for treating hepatitis b virus infections |
| WO2015191907A1 (en) | 2014-06-11 | 2015-12-17 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| US9765050B2 (en) * | 2014-12-30 | 2017-09-19 | Novira Therapeutics, Inc. | Pyridyl reverse sulfonamides for HBV treatment |
| EP3271019A1 (en) * | 2015-03-19 | 2018-01-24 | Novira Therapeutics Inc. | Azocane and azonane derivatives and methods of treating hepatitis b infections |
| US10442788B2 (en) | 2015-04-01 | 2019-10-15 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| AU2016249021A1 (en) | 2015-04-17 | 2017-10-19 | Assembly Biosciences, Inc. | Hepatitis B viral assembly effectors |
| US10738035B2 (en) | 2015-05-13 | 2020-08-11 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| US10179131B2 (en) | 2015-07-13 | 2019-01-15 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US10301255B2 (en) | 2015-07-22 | 2019-05-28 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| TWI730985B (zh) * | 2015-09-15 | 2021-06-21 | 美商艾森伯利生物科學公司 | B型肝炎核心蛋白質調節劑 |
| HK1259410A1 (zh) | 2015-09-29 | 2019-11-29 | 诺维拉治疗公司 | 乙型肝炎抗病毒剂的晶体形式 |
| WO2017136403A1 (en) | 2016-02-02 | 2017-08-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| KR101857714B1 (ko) * | 2016-02-05 | 2018-05-15 | 연세대학교 산학협력단 | 신규 아미드 화합물 및 이의 용도 |
| JP6904970B2 (ja) | 2016-03-07 | 2021-07-21 | エナンタ ファーマシューティカルズ インコーポレイテッド | Ｂ型肝炎抗ウイルス剤 |
| US10752584B2 (en) * | 2016-03-09 | 2020-08-25 | Emory University | Elimination of hepatitis B virus with antiviral agents |
| SG10202011827YA (en) | 2016-04-15 | 2021-01-28 | Novira Therapeutics Inc | Combinations and methods comprising a capsid assembly inhibitor |
| CN109843296A (zh) | 2016-06-10 | 2019-06-04 | 英安塔制药有限公司 | 乙型肝炎抗病毒药剂 |
| EP3500294A4 (en) | 2016-08-22 | 2020-07-29 | Arbutus Biopharma Corporation | ANTI-PD-1 ANTIBODIES, OR THEIR FRAGMENTS, FOR THE TREATMENT OF HEPATITIS B |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| AU2017326356A1 (en) | 2016-09-15 | 2019-04-11 | Assembly Biosciences, Inc. | Hepatitis B core protein modulators |
| TWI794190B (zh) | 2016-11-07 | 2023-03-01 | 加拿大商愛彼特生物製藥公司 | 含有取代的吡啶酮之三環化合物及其使用方法 |
| CN109843855B (zh) * | 2016-11-08 | 2021-06-25 | 正大天晴药业集团股份有限公司 | 作为cccDNA抑制剂的磺酰胺类化合物 |
| AU2018217664B2 (en) * | 2017-02-07 | 2022-03-03 | Janssen Pharmaceutica Nv | Sulphamoylaryl derivatives and use thereof as medicaments for the treatment of liver fibrosis |
| RU2650610C1 (ru) | 2017-02-28 | 2018-04-16 | Васильевич Иващенко Александр | Противовирусная композиция и способ ее применения |
| SG11201908012SA (en) | 2017-03-02 | 2019-09-27 | Assembly Biosciences Inc | Cyclic sulfamide compounds and methods of using same |
| EP3596070A1 (en) | 2017-03-13 | 2020-01-22 | Assembly Biosciences, Inc. | Process for making hepatitis b core protein modulators |
| AU2018238138A1 (en) | 2017-03-21 | 2019-10-17 | Arbutus Biopharma Corporation | Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same |
| US11130740B2 (en) | 2017-04-25 | 2021-09-28 | Arbutus Biopharma Corporation | Substituted 2,3-dihydro-1H-indene analogs and methods using same |
| EP3628674A4 (en) | 2017-05-04 | 2020-11-25 | Shanghai Longwood Biopharmaceuticals Co., Ltd. | BICYCLIC NUCLEOCAPSID INHIBITORS AND THEIR USE AS MEDICINAL PRODUCTS IN THE TREATMENT OF HEPATITIS B. |
| KR20200020887A (ko) | 2017-06-27 | 2020-02-26 | 얀센 파마슈티카 엔.브이. | 헤테로아릴디히드로피리미딘 유도체 및 b형 간염 감염의 치료 방법 |
| CN109251158B (zh) * | 2017-07-14 | 2023-05-23 | 上海长森药业有限公司 | 硫脒酰胺类化合物及其用于乙型肝炎治疗的用途 |
| CN109251212A (zh) * | 2017-07-14 | 2019-01-22 | 上海长森药业有限公司 | 内环硫醚酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途 |
| US10952978B2 (en) | 2017-08-28 | 2021-03-23 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| TW201912153A (zh) * | 2017-08-30 | 2019-04-01 | 加拿大商愛彼特生物製藥公司 | 用於治療ｂ型肝炎的化合物、醫藥組合物及方法 |
| MA50520A (fr) | 2017-11-02 | 2020-09-09 | Aicuris Gmbh & Co Kg | Nouveaux indole-2-carboxamides à substitution pyrazolo-pipéridine hautement actifs agissant contre le virus de l'hépatite b (vhb) |
| JP2021501764A (ja) | 2017-11-02 | 2021-01-21 | アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | Ｂ型肝炎ウイルス（ｈｂｖ）に対して有効な新規高活性アミノチアゾール置換インドール−２−カルボキサミド |
| CN111247131B (zh) * | 2017-11-16 | 2022-02-18 | 正大天晴药业集团股份有限公司 | 抗HBV的四氢异噁唑并[4,3-c]吡啶类化合物 |
| EP3710455A1 (en) * | 2017-11-17 | 2020-09-23 | Novartis AG | Novel dihydroisoxazole compounds and their use for the treatment of hepatitis b |
| TW201936192A (zh) | 2017-12-06 | 2019-09-16 | 美商因那塔製藥公司 | B 型肝炎抗病毒試劑 |
| TW201927789A (zh) | 2017-12-06 | 2019-07-16 | 美商因那塔製藥公司 | B型肝炎抗病毒試劑 |
| WO2019118358A1 (en) | 2017-12-11 | 2019-06-20 | VenatoRx Pharmaceuticals, Inc. | Hepatitis b capsid assembly modulators |
| US11058678B2 (en) | 2018-01-22 | 2021-07-13 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| PL3759109T3 (pl) | 2018-02-26 | 2024-03-04 | Gilead Sciences, Inc. | Podstawione związki pirolizyny jako inhibitory replikacji hbv |
| CN111801331A (zh) | 2018-02-28 | 2020-10-20 | 诺华股份有限公司 | 吲哚-2-羰基化合物及其用于治疗乙型肝炎的用途 |
| CA3090125A1 (en) | 2018-03-14 | 2019-09-19 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
| US12083118B2 (en) | 2018-03-29 | 2024-09-10 | Arbutus Biopharma Corporation | Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same |
| WO2019191166A1 (en) | 2018-03-29 | 2019-10-03 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| WO2019206072A1 (zh) * | 2018-04-24 | 2019-10-31 | 浙江海正药业股份有限公司 | 磺酰胺芳基甲酰胺衍生物及其制备方法和用途 |
| DE202019005471U1 (de) | 2018-06-11 | 2020-09-17 | VenatoRx Pharmaceuticals, Inc. | Hepatitis B Kapsid-Assemblierungsmodulatoren |
| EP3597653A1 (en) | 2018-07-19 | 2020-01-22 | Irbm S.P.A. | Cyclic inhibitors of hepatitis b virus |
| EP3597637A1 (en) * | 2018-07-19 | 2020-01-22 | Irbm S.P.A. | Inhibitors of hepatitis b virus |
| TWI869058B (zh) | 2018-07-27 | 2025-01-01 | 加拿大商愛彼特生物製藥公司 | 經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法 |
| CN108863860B (zh) * | 2018-07-27 | 2021-08-06 | 温州医科大学 | 一种n-取代苯基-3-磺酰氨基苯甲酰胺类化合物及其制备和抗乳腺癌活性的应用 |
| CN108997176B (zh) * | 2018-07-27 | 2021-07-02 | 温州医科大学 | 一种4-氯-n-取代苯基-3-磺酰氨基苯甲酰胺类化合物及其制备和抗肿瘤应用 |
| US11053235B2 (en) | 2018-08-09 | 2021-07-06 | Janssen Sciences Ireland Unlimited Company | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases |
| EP3608326A1 (en) | 2018-08-10 | 2020-02-12 | Irbm S.P.A. | Tricyclic inhibitors of hepatitis b virus |
| UY38383A (es) | 2018-09-21 | 2020-04-30 | Enanta Pharm Inc | Heterociclos funcionalizados como agentes antivirales |
| BR112021006403A2 (pt) * | 2018-10-05 | 2021-07-06 | Univ Emory | agentes monômeros e multiméricos anti-hbv |
| TW202028190A (zh) | 2018-10-22 | 2020-08-01 | 美商艾森伯利生物科學公司 | 用於治療hbv之5員雜芳甲醯胺化合物 |
| US20210395751A1 (en) | 2018-10-31 | 2021-12-23 | The University Of Sydney | Compositions and methods for treating viral infections |
| AU2019373679A1 (en) | 2018-11-02 | 2021-05-27 | Aicuris Gmbh & Co. Kg | Novel urea 6,7-dihydro-4H-thiazolo(5,4-c)pyridines active against the hepatitis B virus (HBV) |
| UY38435A (es) | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | Nuevas urea 6,7-dihidro-4h-pirazol[1,5-a] pirazinas activas contra el virus de la hepatitis b (vhb) |
| PY1991603A (es) | 2018-11-02 | 2020-09-17 | Aicuris Gmbh & Co Kg | Nueva 6,7-dihidro-4h-pirazolo [1,5-a] pirazina indole -2-carboxamidas activas contra el virus de la hepatitis b (vhb) |
| PY1991608A (es) | 2018-11-02 | 2022-02-10 | Aicuris Gmbh & Co Kg | Nueva urea 6,7-dihidro-4h-pirazolo [1,5-a] pirazina activas contra el virus de la hepatitis b (vhb) |
| AR116946A1 (es) | 2018-11-02 | 2021-06-30 | Aicuris Gmbh & Co Kg | Derivados de urea 6,7-dihidro-4h-pirazolo[4,3-c]piridinas activas contra el virus de la hepatitis b (vhb) |
| AR117189A1 (es) | 2018-11-02 | 2021-07-21 | Aicuris Gmbh & Co Kg | Derivados de 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activos contra el virus de la hepatitis b (vhb) |
| US11198693B2 (en) | 2018-11-21 | 2021-12-14 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| TW202415643A (zh) | 2018-12-12 | 2024-04-16 | 加拿大商愛彼特生物製藥公司 | 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法 |
| CN111434665B (zh) | 2019-01-11 | 2023-03-10 | 上海长森药业有限公司 | 内环硫脒酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途 |
| MX2021010145A (es) | 2019-02-22 | 2021-09-14 | Janssen Sciences Ireland Unlimited Co | Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb. |
| CN121108187A (zh) | 2019-04-03 | 2025-12-12 | 阿里戈斯治疗公司 | 吡咯化合物 |
| SG11202111236UA (en) | 2019-04-30 | 2021-11-29 | Aicuris Gmbh & Co Kg | Novel indole-2-carboxamides active against the hepatitis b virus (hbv) |
| PH12021552733A1 (en) | 2019-04-30 | 2023-01-16 | Aicuris Gmbh & Co Kg | Novel indolizine-2-carboxamides active against the hepatitis b virus (hbv) |
| SG11202111493WA (en) | 2019-04-30 | 2021-11-29 | Aicuris Gmbh & Co Kg | Novel oxalyl piperazines active against the hepatitis b virus (hbv) |
| PH12021552749A1 (en) | 2019-04-30 | 2022-07-11 | Aicuris Gmbh & Co Kg | Novel phenyl and pyridyl ureas active against the hepatitis b virus (hbv) |
| MA55879A (fr) | 2019-05-06 | 2022-03-16 | Janssen Sciences Ireland Unlimited Co | Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b |
| EP3825318A1 (en) | 2019-11-25 | 2021-05-26 | Promidis S.r.l. | Oxalamido-substituted tricyclic inhibitors of hepatitis b virus |
| UY38705A (es) | 2019-05-23 | 2020-12-31 | Irbm S P A | Inhibidores tricíclicos sustituidos con oxalamido del virus de hepatitis b |
| EP3741762A1 (en) | 2019-05-23 | 2020-11-25 | Irbm S.P.A. | Oxalamido-substituted tricyclic inhibitors of hepatitis b virus |
| SG11202112590WA (en) | 2019-05-24 | 2021-12-30 | Assembly Biosciences Inc | Pharmaceutical compositions for the treatment of hbv |
| WO2020247444A1 (en) | 2019-06-03 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| WO2020247561A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| WO2020247575A1 (en) * | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| US11738019B2 (en) | 2019-07-11 | 2023-08-29 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| US11236108B2 (en) | 2019-09-17 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| AU2020408039A1 (en) | 2019-12-20 | 2022-08-18 | Arbutus Biopharma Corporation | Synthetic processes and intermediates |
| WO2021188414A1 (en) | 2020-03-16 | 2021-09-23 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| CN111393391B (zh) * | 2020-04-16 | 2022-07-26 | 南京安纳康生物科技有限公司 | 用于乙型肝炎病毒感染的抗病毒剂 |
| CN111349056B (zh) * | 2020-04-16 | 2022-08-02 | 南京安纳康生物科技有限公司 | 用于乙型肝炎病毒感染的抗病毒剂 |
| US20230295096A1 (en) | 2020-04-22 | 2023-09-21 | Assembly Biosciences, Inc. | Pyrazole carboxamide compounds for treatment of hbv |
| WO2021216661A1 (en) | 2020-04-22 | 2021-10-28 | Assembly Biosciences, Inc. | Pyrazole carboxamide compounds for treatment of hbv |
| WO2021216660A1 (en) | 2020-04-22 | 2021-10-28 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
| CA3180706A1 (en) | 2020-04-22 | 2021-10-28 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
| WO2023069544A1 (en) | 2021-10-20 | 2023-04-27 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
| WO2023069547A1 (en) | 2021-10-20 | 2023-04-27 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
| WO2023069545A1 (en) | 2021-10-20 | 2023-04-27 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
| WO2023164186A1 (en) | 2022-02-25 | 2023-08-31 | Assembly Biosciences, Inc. | Benzothia(dia)zepine compounds for treatment of hbv and hdv |
| WO2023164183A1 (en) | 2022-02-25 | 2023-08-31 | Assembly Biosciences, Inc. | Benzothia(dia)zepine compounds for treatment of hbv and hdv |
| WO2023164181A1 (en) | 2022-02-25 | 2023-08-31 | Assembly Biosciences, Inc. | Benzothia(dia)zepine compounds for treatment of hbv and hdv |
| WO2023164179A1 (en) | 2022-02-25 | 2023-08-31 | Assembly Biosciences, Inc. | Benzothia(dia)zepine compounds for treatment of hbv and hdv |
| WO2023175184A1 (en) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer |
| WO2023175185A1 (en) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer |
| CN115677545B (zh) * | 2022-10-28 | 2024-03-15 | 潍坊医学院 | 一种抗hbv磺胺苯甲酰胺类衍生物及其制备方法和应用 |
| WO2025043094A1 (en) | 2023-08-23 | 2025-02-27 | Assembly Biosciences, Inc. | Benzothia(dia)zepine compounds for treatment of hbv and hdv |
| WO2025046148A1 (en) | 2023-09-01 | 2025-03-06 | Forx Therapeutics Ag | Novel parg inhibitors |
| WO2026038156A1 (en) | 2024-08-15 | 2026-02-19 | Assembly Biosciences, Inc. | Novel crystalline forms |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US422547A (en) * | 1890-03-04 | Knife | ||
| US3055905A (en) | 1958-03-04 | 1962-09-25 | Geigy Chem Corp | New sulphamyl benzamides |
| GB912060A (en) | 1960-05-09 | 1962-12-05 | British Drug Houses Ltd | 4-chloro-3-sulphamylbenzanilides |
| GB921520A (en) | 1960-10-10 | 1963-03-20 | British Drug Houses Ltd | 4-fluoro and 4-bromo-3-sulphamylbenzanilides |
| US3602786A (en) * | 1970-06-22 | 1971-08-31 | Georgy Ignatievich Izhelya | Induction linear electric motor |
| US4115155A (en) * | 1974-05-03 | 1978-09-19 | Bethlehem Steel Corporation | Low carbon high yield and tensile strength steel and method of manufacture |
| GB9109557D0 (en) * | 1991-05-02 | 1991-06-26 | Wellcome Found | Chemical compounds |
| JPH0959236A (ja) | 1995-08-23 | 1997-03-04 | Dai Ichi Seiyaku Co Ltd | ベンズアミド化合物 |
| US5939423A (en) * | 1997-04-16 | 1999-08-17 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis B infection with thymosin alpha 1 and famciclovir |
| GB9800750D0 (en) | 1998-01-14 | 1998-03-11 | Lilly Co Eli | Pharmaceutical compound |
| WO2006044645A2 (en) * | 2004-10-13 | 2006-04-27 | Adolor Corporation | Sulfamoyl benzamides and methods of their use |
| US8153803B2 (en) | 2006-07-18 | 2012-04-10 | The General Hospital Corporation | Compositions and methods for modulating sirtuin activity |
| US20080021063A1 (en) * | 2006-07-18 | 2008-01-24 | Kazantsev Aleksey G | Compositions and methods for modulating sirtuin activity |
| US20100016310A1 (en) * | 2006-08-17 | 2010-01-21 | Boehringer Ingelheim International Gmbh | Methods of using aryl sulfonyl compounds effective as soluble epoxide hydrolase inhibitors |
| AU2008287542C1 (en) * | 2007-06-01 | 2015-01-22 | The Trustees Of Princeton University | Treatment of viral infections by modulation of host cell metabolic pathways |
| WO2009018219A2 (en) * | 2007-07-28 | 2009-02-05 | University Of Chicago | Methods and compositions for modulating rad51 and homologous recombination |
| CA2695071A1 (en) * | 2007-08-02 | 2009-02-05 | F. Hoffmann-La Roche Ag | The use of benzamide derivatives for the treatment of cns disorders |
| CA2709784A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| US20100009970A1 (en) * | 2008-03-19 | 2010-01-14 | Combinatorx (Singapore) Pte. Ltd. | Compositions and methods for treatment of viral diseases |
| WO2009131065A1 (ja) * | 2008-04-24 | 2009-10-29 | 萬有製薬株式会社 | アリールスルホニル誘導体を有効成分とする長鎖脂肪酸伸長酵素阻害剤 |
| FR2933698A1 (fr) | 2008-07-09 | 2010-01-15 | Servier Lab | Nouveaux derives de benzothiadiazines cycloalkylees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| WO2010123139A1 (ja) * | 2009-04-24 | 2010-10-28 | 持田製薬株式会社 | スルファモイル基を有するアリールカルボキサミド誘導体 |
| EP3085368A1 (en) | 2011-07-01 | 2016-10-26 | Baruch S. Blumberg Institute | Sulfamoylbenzamide derivatives as antiviral agents against hbv infection |
| WO2013096744A1 (en) * | 2011-12-21 | 2013-06-27 | Novira Therapeutics, Inc. | Hepatitis b antiviral agents |
| CN104822267B (zh) * | 2012-02-29 | 2018-01-23 | 巴鲁克·S·布伦博格研究所 | 乙型肝炎病毒共价闭合环状dna形成的抑制剂及其使用方法 |
-
2012
- 2012-06-29 EP EP16174324.0A patent/EP3085368A1/en not_active Withdrawn
- 2012-06-29 CN CN201280039363.5A patent/CN103889953B/zh not_active Expired - Fee Related
- 2012-06-29 US US14/130,140 patent/US9399619B2/en active Active
- 2012-06-29 JP JP2014519057A patent/JP5977347B2/ja not_active Expired - Fee Related
- 2012-06-29 CN CN201610312350.0A patent/CN106166157B/zh not_active Expired - Fee Related
- 2012-06-29 WO PCT/US2012/044775 patent/WO2013006394A1/en not_active Ceased
- 2012-06-29 EP EP12807810.2A patent/EP2726459B1/en active Active
-
2015
- 2015-12-18 US US14/975,239 patent/US9758477B2/en active Active
-
2016
- 2016-07-21 JP JP2016143481A patent/JP6516705B2/ja not_active Expired - Fee Related
-
2017
- 2017-07-21 US US15/656,769 patent/US20170320818A1/en not_active Abandoned
-
2019
- 2019-04-16 JP JP2019077562A patent/JP2019151639A/ja active Pending
- 2019-07-02 US US16/459,665 patent/US20190337891A1/en not_active Abandoned
-
2020
- 2020-11-23 US US17/101,852 patent/US20210070703A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014523901A5 (https=) | ||
| US10995064B2 (en) | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B | |
| JP6409001B2 (ja) | Ｈｂｖ感染に対する新規抗ウイルス剤 | |
| JP5977347B2 (ja) | Ｈｂｖ感染に対する抗ウイルス剤としてのスルファモイルベンズアミド誘導体 | |
| JP6271806B2 (ja) | ウイルス静止化合物としての抗炎症剤 | |
| JP5399237B2 (ja) | ヒトパピローマウイルス阻害剤としてのピペリジン誘導体 | |
| JP6484168B2 (ja) | 抗ウイルス活性を有するメタンチオン化合物 | |
| CN115916345B (zh) | 吡咯并吡啶衍生物及其用途 | |
| US9951058B2 (en) | Compound, pharmaceutically acceptable salt or optical isomer thereof, method for preparing the same, and pharmaceutical composition for prevention or treatment of viral diseases containing same as active ingredient | |
| JP5547082B2 (ja) | 新規なヒトパピローマウイルス阻害剤およびそれを含有する医薬組成物 | |
| CN105263926B (zh) | 苯并噻吩化合物 | |
| HK40129041A (en) | Compound, pharmaceutically acceptable salt or optical isomer thereof, method for preparing same, and pharmaceutical composition for prevention or treatment of viral diseases containing same as active ingredient | |
| HK40059923A (en) | Compound, pharmaceutically acceptable salt or optical isomer thereof, method for preparing same, and pharmaceutical composition for prevention or treatment of viral diseases containing same as active ingredient | |
| HK40059923B (en) | Compound, pharmaceutically acceptable salt or optical isomer thereof, method for preparing same, and pharmaceutical composition for prevention or treatment of viral diseases containing same as active ingredient | |
| CN120923428A (zh) | 流感病毒核酸内切酶抑制剂及其应用 | |
| US20160280669A1 (en) | Compounds and methods | |
| HK1216253B (en) | Novel compound, pharmaceutically acceptable salt or optical isomer thereof, method for preparing same, and pharmaceutical composition for prevention or treatment of viral diseases containing same as active ingredient | |
| OA17199A (en) | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B. |